Comparison of clinical results between high grade patterns in stage I lung adenocarcinoma

Hyun Woo Jeon¹ | Young-Du Kim¹ | Sung Bo Sim¹ | Mi Hyoung Moon²

¹Department of Thoracic and Cardiovascular Surgery, Bucheon St. Mary’s Hospital, College of Medicine, The Catholic University of Korea, Seoul, Republic of Korea
²Department of Thoracic and Cardiovascular Surgery, Seoul St. Mary’s Hospital, College of Medicine, The Catholic University of Korea, Seoul, Republic of Korea

Correspondence
Hyun Woo Jeon, Department of Thoracic and Cardiovascular Surgery, Bucheon St. Mary’s Hospital, The Catholic University of Korea, 222 Banpo-daero, Seocho-gu, Seoul, 137-701, Republic of Korea.
Email: ulnazoro@catholic.ac.kr

Abstract

Background: The histological subtype has been introduced in invasive lung adenocarcinoma. The predominant micropapillary and solid subtypes are categorized as high-grade patterns and provide a worse prognosis. However, the prognostic analysis of high-grade patterns has not previously been fully investigated. Thus, this study aimed to investigate the prognostic role of high-grade patterns in pathological stage I lung adenocarcinoma.

Methods: Patients with stage I lung adenocarcinoma and micropapillary or solid components were reviewed. Clinicopathological features and clinical course were compared in these subtypes, and prognostic factors were analyzed in high-grade patterns.

Results: The patients were classified into five groups based on the presence of micropapillary or solid subtypes, namely, micropapillary predominant, solid predominant, both nonpredominant subtypes, only minor micropapillary subtype, and only minor solid subtype present. Disease-free interval was significantly different, and the micropapillary predominant group showed worse disease-free interval (p = 0.001). Contrastingly, the solid predominant group showed significantly worse overall survival among high-grade patterns (p = 0.035). The multivariate analysis revealed an association between smoking, micropapillary predominant, blood vessel invasion, and visceral pleural invasion with recurrence and more association between solid predominant and visceral pleural invasion with overall survival.

Conclusions: Clinical results were different in stage I high-grade adenocarcinoma. The predominant micropapillary subtype is the independent prognostic factor for recurrence. However, the solid subtype is the significant factor for overall survival. Furthermore, the predominant subtype is the most valuable and independent prognostic factor for predicting recurrence or survival.

Keywords
adenocarcinoma, lung cancer, micropapillary, solid

INTRODUCTION

Adenocarcinoma is most common in lung cancer.¹ The most prominent feature is pathological heterogeneous.² A new classification of lung adenocarcinoma, according to the histological subtype, has been adopted by the World Health Organization (WHO) in 2015.³ Lung adenocarcinoma has been categorized by the predominant pattern after histological subtype quantification in 5% increments because adenocarcinoma varies in terms of histological subtype and proportion. The prognosis is significantly different according to the histological subtype despite the same stage. Lepidic predominant subtype as low-grade has a favorable result and acinar and papillary subtypes are intermediate grade. Micropapillary (MP) or solid predominant (SP) subtypes as high-grade patterns have worse prognosis, despite curative resection in early-stage lung adenocarcinoma.⁴ High-grade patterns are associated with smoking, lymphatic vessel invasion (LVI), and nonground-glass opacity (GGO) lesions, which are prognostic factors in lung cancer.⁵ Furthermore, high-grade patterns showed early lymph node (LN) metastasis, higher metastatic activity, visceral pleural invasion, and spread
through air spaces (STAS). \(^6\)–\(^8\) Additionally, the presence of these high-grade patterns without a predominant subtype also shows unfavorable results. \(^9\), \(^10\) However, these studies were analyzed in comparison with non-MP or solid subtypes and some studies demonstrated that MP or solid nonpredominant components did not show a worse prognosis. \(^11\) A few studies were found on prognostic analysis in lung adenocarcinoma among MP and solid subtypes. We hypothesized that MP and solid subtypes have different clinicopathological features despite categorized high-grade patterns. The present study reviewed patients with MP or solid subtypes, including predominant and nonpredominant subtypes after curative resection in stage I lung adenocarcinoma. Additionally, the clinicopathological features were investigated and the prognostic factors were analyzed.

**METHODS**

We reviewed the electronic medical records of patients who underwent curative resection for invasive lung adenocarcinoma from January 2010 to April 2017 at Seoul and Bucheon St. Mary’s Hospital. This retrospective study was conducted with the approval of the Institutional Review Board of the Catholic Medical Center (Republic of Korea). Written informed consent from the patients was waived because of the retrospective nature of the study. We classified the pathological stage of patients according to the eighth edition of the tumor-node-metastasis (TNM) classification. Patients with pathological stage I were included in the study. Among these patients, those with adenocarcinoma in situ, minimally invasive adenocarcinoma, multifocal GGO, neoadjuvant chemotherapy, and missing medical records were excluded, as well as patients with incomplete resection, wedge resection, and perioperative death. Additionally, patients without mediastinal node evaluation during surgery and patients with coexistence of other malignancies were also excluded except for a curative state with 5-year disease-free survival. Patients with histological subtypes were classified based on the pathological report. Patients with MP or solid predominant subtype were first included. Patients with the presence of MP or solid components were included according to the histological subtype. Finally, a total of 187 patients with predominant or minor subtypes of high-grade patterns were reviewed (Figure 1).

Preoperative assessments included blood sampling, including carcinoembryonic antigen (CEA), pulmonary function test, chest computed tomography (CT), echocardiography, positron emission tomography-CT (PET-CT), brain magnetic resonance imaging, bone scanning, and bronchoscopy.

We reviewed the CEA level and feature of the main tumor on chest CT, which was a solid mass or part-solid nodule. The maximum standardized uptake value (SUVmax) was reviewed on PET-CT.

Patients were classified into the five groups by the proportion of MP or solid subtype as follows: (1) MP predominant (MPP), (2) solid predominant (SP), (3) MP and solid components but not predominant (MP\(^+\)/S\(^+\)), (4) only MP components but not predominant (MP\(^+\)/S\(^-\)), (5) only solid components but not predominant (MP\(^-\)/S\(^+\)).

Follow-up (F/U) was conducted every 3 months for 1 year after the operation, every 4 months in the second year, and every 6 months thereafter. Chest CT evaluation

**FIGURE 1** Diagram of patient selection
was conducted on every visit. All patients were followed until recurrence and death or loss of F/U. Recurrence was defined as local or extrathoracic metastasis based on clinical and pathological evidence. Overall survival (OS) was defined as the interval from operation to the date of death, or final follow-up visit. Disease-free interval (DFI) was defined as the interval from operation to the date of local or distant metastasis.

**Statistical analysis**

All statistical analyses were conducted using the statistical package for the social sciences version 18 (SPSS Inc.). Clinicopathological factors were compared according to the high grade patterns. Continuous variables were compared using the Kruskal–Wallis test, and categorical variables were compared using the chi-square test.

The survival curves of DFI and OS were conducted using the Kaplan–Meier method and log-rank test was used to identify the differences among these groups.

Multivariate analysis was used to assess the effect of the covariates on DFI and OS using the Cox proportional hazards model after checking the proportionality assumption. Variables with p-values of <0.05 in the univariate analysis were included in the multivariate analysis.

**RESULTS**

Patient characteristics are demonstrated in Table 1. The median age of patients was 64 years (range, 36–85). Patients included 92 (49.2%) males, and patients who were current smokers or with a smoking history accounted for 69 (36.9%).

The preoperative level of CEA was median 2 (range, 0.49–25.83). Preoperative CT identified part-solid nodules in 60 (32.1%) patients. No pure GGOs were identified. PET-CT revealed a median SUV max of 5 (range, 0.8–17.6).

The pathological data (Table 2) revealed a median tumor size of 2.3 cm (range, 0.7–4). Well differentiated tumors were rare. Acinar predominant tumors were the most common histological subtype (50.8%). Meanwhile, the lepidic predominant subtype was rare despite its early-stage (8.6%). MPP and SP were determined in 13 and 42 patients, respectively (7% and 22.5%). Recently, a new grading system has been proposed for lung adenocarcinoma, and a cutoff value of 20% in patients with high-grade patterns had worse prognoses. In this grading system for investigation, MP components of ≥20% were identified in 50 (26.7%) patients and solid patterns of ≥20% in 67 (35.8%) patients. LVI was identified in 95 (50.8%) patients, blood vessel invasion (BVI) in 32 (17.1%), and visceral pleural invasion (VPI) in 47 (25.1%). A total of 122 patients were pathologically staged as IA (65.2%) and 65 (34.8%) as stage IB. Platinum-based adjuvant chemotherapy was conducted in 13 (6.9%) patients.

Patients were classified into the five groups by the proportion of MP or solid subtype (Table 3). Age was not significantly different in the five groups (p = 0.633). The SP
group revealed more male predominance ($p = 0.001$) compared with other groups, and smoking ($p = 0.055$) and poor differentiation ($p < 0.001$) were also more associated with SP. The MP+/S− group had the lowest median value of SUVmax ($p < 0.001$), which was more associated with mixed GGO lesion ($p < 0.001$) and well differentiation ($p < 0.001$). The lepidic predominant subtype was more common in the MP+ S/C0 group ($p = 0.078$).

The MP group showed the largest tumor size at that time of operation ($p = 0.011$). However, LVI, BVI, and VPI showed no significant difference among the five groups. For the epidermal growth factor receptor (EGFR), the SP group was less associated with EGFR expression compared with other groups ($p = 0.005$) (Table 4).

During the F/U period (median F/U of 60 months), 55 (29.4%) recurrences and 13 (7%) deaths were identified, according to the survival curve for DSI and OS (Figure 2). The cause of death was cancer-related. A significant difference was found in DFI, and recurrence was the most common in the MPP group ($p = 0.001$). However, the SP group was the most associated with death for OS ($p = 0.035$) (Table 5).

Of the 55 patients with recurrence, bone metastasis was identified in seven patients. Pleural metastasis was identified

### Table 3

|                | MP+/S+ (n = 21) | MP+/S− (n = 77) | MP−/S+ (n = 34) | MPP (n = 13) | SP (n = 42) | p-value |
|----------------|-----------------|-----------------|-----------------|-------------|------------|---------|
| Age            | 66 (38–80)      | 64 (38–82)      | 66 (38–85)      | 64 (51–80)  | 67 (42–82) | 0.633   |
| Male           | 12 (57)         | 30 (39)         | 12 (32.4)       | 6 (46.2)    | 32 (76.2)  | 0.001   |
| Smoking        | 8 (38.1)        | 20 (26)         | 15 (40.5)       | 4 (30.8)    | 22 (52.4)  | 0.055   |
| CEA            | 1.76 (0.5–5.59) | 1.71 (0.49–19.15) | 2.69 (0.5–25.83) | 2.28 (0.85–6) | 1.97 (0.5–19.13) | < 0.001 |
| SUVmax         | 5.47 (2.1–14.55) | 3.5 (0.8–17.6)  | 5.8 (1.4–14.6)  | 6.5 (2.1–17.4) | 6.82 (1.7–17.14) | < 0.001 |
| Mixed GGO      | 5 (23.8)        | 38 (49.4)       | 10 (27)         | 2 (15.4)    | 5 (11.9)   | < 0.001 |
| Lobectomy      | 18 (85.7)       | 69 (89.6)       | 32 (94.1)       | 13 (100)    | 40 (95.2)  | 0.455   |
| Size           | 2.5 (1.5–3.9)   | 2 (0.8–4)       | 2.45 (0.9–4)    | 3.3 (0.7–4) | 2.25 (0.9–4) | 0.011   |
| Differentiation|                |                 |                 |             |            |         |
| Well           | 0 (0)           | 19 (24.7)       | 0 (0)           | 0 (0)       | 1 (2.4)    | < 0.001 |
| Poorly         | 8 (38.1)        | 9 (11.7)        | 7 (20.6)        | 4 (30.8)    | 29 (69.1)  | < 0.001 |
| Predominant subtype |         |                 |                 |             |            |         |
| Acinar         | 15 (71.4)       | 51 (66.2)       | 29 (85.3)       | 0 (0)       | 0 (0)      | < 0.001 |
| Lepidic        | 2 (9.5)         | 11 (14.3)       | 3 (8.8)         | 0 (0)       | 0 (0)      | 0.078   |
| LVI            | 13 (61.9)       | 38 (49.4)       | 20 (58.8)       | 9 (69.2)    | 15 (35.7)  | 0.109   |
| BVI            | 4 (19)          | 9 (11.7)        | 8 (23.5)        | 2 (15.4)    | 9 (21.4)   | 0.522   |
| VPI            | 6 (28.6)        | 17 (22.1)       | 8 (23.5)        | 3 (23.1)    | 13 (31)    | 0.854   |
| EGFR           | 9 (42.9)        | 48 (62.3)       | 18 (52.9)       | 6 (46.2)    | 11 (26.2)  | 0.005   |
| Stage IB       | 10 (47.6)       | 15 (19.5)       | 15 (44.1)       | 9 (61.5)    | 17 (40.5)  | 0.004   |
| Adjuvant Tx    | 1 (4.8)         | 2 (2.6)         | 1 (2.9)         | 3 (23.1)    | 6 (14.3)   | 0.018   |

Data are presented as the median (minimum–maximum) or frequencies and percentages as appropriate.

Abbreviations: BVI, blood vessel invasion; CEA, carcinoembryonic antigen; GGO, ground-glass opacity; LVI, lymphatic vessel invasion; SUVmax, maximum standardized uptake value; VPI, visceral pleural invasion.

### Table 4

|                | Univariate | Multivariate |
|----------------|------------|--------------|
| Variables      | HR         | 95% CI       | p-value | HR         | 95% CI       | p-value |
| Smoking        | 2.172      | 1.279–3.690  | 0.004   | 2.440      | 1.423–4.184  | 0.001   |
| SUVmax         | 1.088      | 1.023–1.156  | 0.007   |            |              |         |
| Non-GGO (solid mass) | 2.696   | 1.355–5.366  | 0.005   | 4.136      | 1.982–8.631  | <0.001 |
| MPP            | 3.413      | 1.665–6.996  | 0.001   | 2.338      | 1.366–4.002  | 0.002   |
| MP ≥ 20%       | 2.338      | 1.366–4.002  | 0.002   | 2.571      | 1.431–4.618  | 0.002   |
| BVI            | 2.088      | 1.279–3.813  | 0.004   | 2.083      | 1.187–3.658  | 0.011   |

Abbreviations: BVI, blood vessel invasion; GGO, ground-glass opacity; MP, micropapillary; MPP, micropapillary predominant; SUVmax, maximum standardized uptake value; VPI, visceral pleural invasion.
in 10 patients. Lung to lung metastasis was noted in 15 patients. LN metastasis was in eight patients. Two patients had recurrence from the bronchial stump with mediastinal LN metastasis. The other patients showed distant metastasis. A total of 49 patients received chemotherapy, radiotherapy, or tyrosine kinase inhibitor (TKI). Others refused treatment. The MP+ group showed that eight patients had a postoperative recurrence. EGFR expression was determined in four patients, one patient received TKI, and seven patients had chemo- or radiotherapy. A total of 15 patients showed recurrence in the MP+/S+ group. Among them, 12 showed EGFR expression and 10 received TKI. SP shows EGFR expression in four patients. Chemoradiotherapy was conducted in four patients and TKI treatment in three patients. A total of nine patients showed recurrence in the MP−/S+ group. EGFR expression was identified in four patients. Chemoradiotherapy was conducted in four patients and TKI treatment in three patients. A total of nine patients showed recurrence in the MP−/S− group. EGFR expression was identified in four patients, and three patients were treated with TKI and patients with chemoradiotherapy. A total of 14 patients showed recurrence in SP. EGFR expression was determined in seven patients, six patients were given TKI and seven underwent chemoradiotherapy. The univariate analysis for DFI revealed that smoking (p = 0.004), SUVmax (p = 0.007), non-GGO lesion (p = 0.005), MPP (p = 0.001), MP of ≥20% (p = 0.002), BVI (p = 0.002), and VPI (p = 0.012) were associated with DFI. Multivariate analysis revealed that smoking (p = 0.001), MPP (p < 0.001), BVI (p = 0.002), and VPI (p = 0.011) were significant prognostic factors for DFI (Table 4).

The survival analysis for OS revealed that age (p = 0.028), smoking (p = 0.008), SUVmax (p = 0.046), SP (p = 0.005), and VPI (p = 0.005) were associated with OS using the univariate analysis. The multivariate analysis revealed that smoking (p = 0.032), SP (p = 0.038), and VPI (p = 0.016) were significant prognostic factors for OS (Table 5).

DISCUSSION

Lung adenocarcinoma is the most common in non-small cell lung cancer, and early-stage lung adenocarcinoma is the best option for surgical resection, with a curative goal. However, lung cancer is one of the worst prognostic diseases and is the leading cause of death. Stage IA lung adenocarcinoma has the most survival postoperative benefit. However, clinical results remain unsatisfactory, and the 5-year survival rate is approximately 70%–90%. The prognostic factor analysis is important to predict recurrence and conduct effective treatment. The TNM staging system is a well-known classification for lung cancer. However, predicting the prognosis in early-stage lung adenocarcinoma has many limitations. A new histological subtype classification was...
The WHO adopted this proposal and indicated that however, these statistical results came from the analysis in comparison with nonhigh-grade patterns. We wondered whether the clinical course is the same between two high-grade patterns despite different clinico-pathological features. In our study, 55 patients with high-grade patterns experienced recurrence after curative resection in stage I lung adenocarcinoma. The recurrence rate was relatively high (29.4%). Yoshizawa et al. conducted a validation study for the adenocarcinoma classification with East Asian patients and found that the 5-year DFS of MP predominant (0%) was significantly lower than the 5-year DFS of patients with solid subtype (43.3%). This result is exactly analogous to our study result. In our study, the 5-year DFI rate of the MP predominant subtype was only 38%, which is the independent prognostic factor for recurrence, and the tumor size of the MP predominant subtype was larger than other subtypes at that time of surgery. Yoshizawa et al. reported that MP and SP subtype were not distinct for OS, although DFS for MP was much lower than the SP subtype. EGFR mutations were more frequent in the MP predominant subtype than in the solid subtype and survival was increased because of more EGFR-TK susceptibility. Warth et al. indicated that post recurrence survival was significantly decreased in the SP subtype, which was rarely associated with EGFR mutations. This means that the effects of TKIs are unsatisfactory. However, in the recurrence in our study, the frequency of EGFR mutations and TKI treatment was similar between the MP predominant and the SP subtypes. The worse result was that TKI response was much lower in the SP subtype despite EGFR expression mutations.

Some studies have conducted survival analysis according to the proportion of high-grade patterns and demonstrated worse clinical results according to the increased proportion of high-grade patterns. However, the proportion of each subtype did not reach the significance for DFI and OS in our study. In our study, we conclude that the predominant subtype is the most powerful risk factor in the survival analysis. Furthermore, only the nonpredominant MP components showed better clinical outcomes than other subtypes and were associated with more GGO features, well-differentiated, lepidic predominant, and EGFR mutations.

This study had certain limitations, including its retrospective nature and small sample size. MP or solid subtypes are rare in stage I lung adenocarcinoma. However, we focused on the comparison of clinico-pathological features and clinical outcomes between two high-grade patterns, which was the aim of this study. Comparing previous studies, overall survival was relatively high. Only 13 patients died. The reason for this may be the patients that were lost to follow-up in the study. Nowadays, segmentectomy is a surgical option for lesions less than 2 cm. In our study, incidence of segmentectomy was low. Segmentectomy is one of the surgical options in GGO dominant lesions. However, there were no GGO dominant lesions in this study. Finally, this study was not conducted from multiple centers; thus, selection bias may be inevitable.
In conclusion, MP and SP subtypes showed different clinical courses despite being high-grade patterns after curative resection in pathological stage I lung adenocarcinoma. The MP predominant subtype increased in recurrence and the SP subtype decreased in survival. Therefore, a larger study will be needed to determine the prognostic factors among the high-grade patterns.

ACKNOWLEDGMENTS
This manuscript was edited by Enago.

CONFICT OF INTEREST
All authors declare that they have no conflicts of interest associated with this study.

ORCID
Hyun Woo Jeon © https://orcid.org/0000-0003-1539-4359
Mi Hyun Moon © https://orcid.org/0000-0003-2799-4570

REFERENCES
1. Ferlay J, Steliarova-Foucher E, Lortet-Tieulent J, Rosso S, Coebergh JWV, Comber H, et al. Cancer incidence and mortality patterns in Europe: estimates for 40 countries in 2012. Eur J Cancer. 2013;49:1374–403.
2. Tsao MS, Marguet S, Le Teuff G, et al. Subtype classification of lung adenocarcinoma predicts benefit from adjuvant chemotherapy in patients undergoing complete resection. J Clin Oncol. 2015;33:3439–46.
3. Travis WD, Brambilla E, Burke AP, Marx A, Nicholson AG. WHO Classification of Tumours of the Lung, Pleura, Thymus and Heart. 4th ed. Lyon: International Agency for Research on Cancer; 2015.
4. Yanagawa N, Shimoo S, Abiko M, et al. The clinical impact of solid and micropapillary patterns in resected lung adenocarcinoma. J Thorac Oncol. 2016;11:1976–83.
5. Makinen JM, Lahtakari K, Johnson S, Makitaro R, Bloigu R, Piäkkö P, et al. Histological features of malignancy correlate with growth patterns and patient outcome in lung adenocarcinoma. Histopathology. 2017;71:425–36.
6. Yu Y, Jian H, Sheng L, Zhu L, Lu S. Lymph node involvement influenced by lung adenocarcinoma subtypes in tumor size ≤3 cm disease: a study of 2268 cases. Eur J Surg Oncol. 2016;42:1714–9.
7. Nakamura H, Saji H, Shinmyo T, Tagaya R, Kurimoto N, Koizumi H, et al. Close association of IASLC/ATS/ERS lung adenocarcinoma subtypes with glucose-uptake in positron emission tomography. Lung Cancer. 2015;87:28–33.
8. Terada Y, Takahashi T, Morita S, KAshiwabara K, Nagayama K, Nitaodori H, et al. Spread through air space is an independent predictor of recurrence in stage III (N2) lung adenocarcinoma. Interact Cardiovasc Thorac Surg. 2019;29(3):442–8.
9. Chen T, Luo J, Gu H, Gu Y, Huang Q, Wang Y, et al. Impact of solid minor histologic subtype in postsurgical prognosis of stage I lung adenocarcinoma. Ann Thorac Surg. 2018;105:302–8.
10. Zhao Y, Wang R, Shen X, Pan Y, Cheng C, Li Y, et al. Minor components of micropapillary and solid subtypes in lung adenocarcinomas with micropapillary and/or solid patterns: a review. Curr Opin Pulm Med. 2014;20:317–23.
11. Yoshizawa A, Sumiyoshi S, Sonobe M, Kobayashi M, Fujimoto M, Kawakami F, et al. Validation of the IASLC/ATS/ERS lung adenocarcinoma classification for prognosis and association with EGFR and KRAS gene mutations: analysis of 440 Japanese patients. J Thorac Oncol. 2013;8(1):52–61. https://doi.org/10.1097/JTO.0b013e3182769aa8
12. Warth A, Muley T, Meister M, Stenzinger A, Thomas M, Schirmacher P, et al. The novel histologic International Association for the Study of Lung Cancer/International Thoracic Society classification system of lung adenocarcinoma is a stage-independent predictor of survival. J Clin Oncol. 2012;30:1438–46.
13. Yoshida T, Ishii G, Goto K, Yoh K, Niho S, Umemura S, et al. Solid predominant histology predicts EGFR tyrosine kinase inhibitor response in patients with EGFR mutation-positive lung adenocarcinoma. J Cancer Res Clin Oncol. 2013;139(10):1691–700.
14. Zomborì T, Nyári T, Tiszlavicz I, Pálföldi R, Csada E, Géczi T, et al. The more the micropapillary pattern in stage I lung adenocarcinoma, the worse the prognosis-a retrospective study on digitalized slides. Vircows Arch. 2018;472(6):949–58. https://doi.org/10.1007/s00428-018-2337-x

How to cite this article: Jeon HW, Kim Y-D, Sim SB, Moon MH. Comparison of clinical results between high grade patterns in stage I lung adenocarcinoma. Thorac Cancer. 2022;13(17):2473–9. https://doi.org/10.1111/1759-7714.14578